Liver Fatty Acid Composition in Mice with or Without Nonalcoholic Fatty Liver Disease

Overview

Journal Lipids Health Dis

Publisher Biomed Central

Specialties Biochemistry
Endocrinology

Date 2011 Dec 15

PMID 22165986

Citations 29

Authors

Xin Wang

Yuzhen Cao

Yunwei Fu

Guifang Guo

Xiuying Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the most frequent causes of abnormal liver function. Because fatty acids can damage biological membranes, fatty acid accumulation in the liver may be partially responsible for the functional and morphological changes that are observed in nonalcoholic liver disease. The aim of this study was to use gas chromatography-mass spectrometry to evaluate the fatty acid composition of an experimental mouse model of NAFLD induced by high-fat feed and CCl4 and to assess the association between liver fatty acid accumulation and NAFLD. C57BL/6J mice were given high-fat feed for six consecutive weeks to develop experimental NAFLD. Meanwhile, these mice were given subcutaneous injections of a 40% CCl4-vegetable oil mixture twice per week.

Results: A pathological examination found that NAFLD had developed in the C57BL/6J mice. High-fat feed and CCl4 led to significant increases in C14:0, C16:0, C18:0 and C20:3 (P < 0.01), and decreases in C15:0, C18:1, C18:2 and C18:3 (P < 0.01) in the mouse liver. The treatment also led to an increase in SFA and decreases in other fatty acids (UFA, PUFA and MUFA). An increase in the ratio of product/precursor n-6 (C20:4/C18:2) and n-3 ([C20:5+C22:6]/C18:3) and a decrease in the ratio of n-6/n-3 (C20:4/[C20:5+C22:6]) were also observed.

Conclusion: These data are consistent with the hypothesis that fatty acids are deranged in mice with non-alcoholic fatty liver injury induced by high-fat feed and CCl4, which may be involved in its pathogenesis and/or progression via an unclear mechanism.

Citing Articles

Liver magnetic resonance spectroscopy as an alternative for evaluating Niemann-Pick C disease progression.

Xavier A, Oyarzun J, Zacconi F, Zanlungo S, Andia M RSC Adv. 2025; 15(6):4079-4085.

PMID: 39926245 PMC: 11800100. DOI: 10.1039/d4ra06781a.

Evaluation of as a Feed Additive in Low-Protein Diets of Broilers.

Yalcinkaya H, Yalcin S, Ramay M, Onbasilar E, Bakir B, Elibol F Int J Mol Sci. 2025; 26(1.

PMID: 39795890 PMC: 11720351. DOI: 10.3390/ijms26010024.

A Comprehensive Analysis of Liver Lipidomics Signature in Adults with Metabolic Dysfunction-Associated Steatohepatitis-A Pilot Study.

Mouskeftara T, Kalopitas G, Liapikos T, Arvanitakis K, Theocharidou E, Germanidis G Int J Mol Sci. 2024; 25(23).

PMID: 39684777 PMC: 11642547. DOI: 10.3390/ijms252313067.

3,5-Dimethyl-2,4,6-trimethoxychalcone Lessens Obesity and MAFLD in Leptin-Deficient Mice.

Gaige S, Abysique A, Barbouche R, Tonetto A, Di Maio A, Robin M Int J Mol Sci. 2024; 25(18).

PMID: 39337328 PMC: 11432508. DOI: 10.3390/ijms25189838.

Characterization of hepatic fatty acids using magnetic resonance spectroscopy for the assessment of treatment response to metformin in an eNOS mouse model of metabolic nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

Lavin B, Eykyn T, Phinikaridou A, Xavier A, Kumar S, Buque X NMR Biomed. 2023; 36(8):e4932.

PMID: 36940044 PMC: 10704844. DOI: 10.1002/nbm.4932.

References

Mavrelis P, Ammon H, Gleysteen J, Komorowski R, Charaf U . Hepatic free fatty acids in alcoholic liver disease and morbid obesity. Hepatology. 1983; 3(2):226-31. DOI: 10.1002/hep.1840030215. View

Farrell G, Larter C . Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatology. 2006; 43(2 Suppl 1):S99-S112. DOI: 10.1002/hep.20973. View

Tavares de Almeida I, Cortez-Pinto H, Fidalgo G, Rodrigues D, Camilo M . Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis. Clin Nutr. 2002; 21(3):219-23. DOI: 10.1054/clnu.2001.0529. View

Goldberg I, Ginsberg H . Ins and outs modulating hepatic triglyceride and development of nonalcoholic fatty liver disease. Gastroenterology. 2006; 130(4):1343-6. DOI: 10.1053/j.gastro.2006.02.040. View

Fontana L, Moreira E, Torres M, Periago J, Sanchez de Medina F, Gil A . Effects of dietary polyunsaturated fatty acids and nucleotides on tissue fatty acid profiles of rats with carbon tetrachloride-induced liver damage. Clin Nutr. 1999; 18(2):93-101. DOI: 10.1016/s0261-5614(99)80058-2. View

Jansen P . Non-alcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2004; 16(11):1079-85. DOI: 10.1097/00042737-200411000-00001. View

Schievella A, Regier M, Smith W, Lin L . Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum. J Biol Chem. 1995; 270(51):30749-54. DOI: 10.1074/jbc.270.51.30749. View

Freneaux E, Labbe G, Letteron P, The Le Dinh , Degott C, Geneve J . Inhibition of the mitochondrial oxidation of fatty acids by tetracycline in mice and in man: possible role in microvesicular steatosis induced by this antibiotic. Hepatology. 1988; 8(5):1056-62. DOI: 10.1002/hep.1840080513. View

Donnelly K, Smith C, Schwarzenberg S, Jessurun J, Boldt M, Parks E . Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest. 2005; 115(5):1343-51. PMC: 1087172. DOI: 10.1172/JCI23621. View

10.

Barreyro F, Kobayashi S, Bronk S, Werneburg N, Malhi H, Gores G . Transcriptional regulation of Bim by FoxO3A mediates hepatocyte lipoapoptosis. J Biol Chem. 2007; 282(37):27141-27154. DOI: 10.1074/jbc.M704391200. View

11.

Chitturi S, Abeygunasekera S, Farrell G, Holmes-Walker J, Hui J, Fung C . NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology. 2002; 35(2):373-9. DOI: 10.1053/jhep.2002.30692. View

12.

Levy J, Clore J, Stevens W . Dietary n-3 polyunsaturated fatty acids decrease hepatic triglycerides in Fischer 344 rats. Hepatology. 2004; 39(3):608-16. DOI: 10.1002/hep.20093. View

13.

Musso G, Gambino R, Cassader M . Recent insights into hepatic lipid metabolism in non-alcoholic fatty liver disease (NAFLD). Prog Lipid Res. 2008; 48(1):1-26. DOI: 10.1016/j.plipres.2008.08.001. View

14.

Kohjima M, Enjoji M, Higuchi N, Kato M, Kotoh K, Yoshimoto T . Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease. Int J Mol Med. 2007; 20(3):351-8. View

15.

Nebert D, Karp C . Endogenous functions of the aryl hydrocarbon receptor (AHR): intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology. J Biol Chem. 2008; 283(52):36061-5. PMC: 2606007. DOI: 10.1074/jbc.R800053200. View

16.

Pan S, Yang R, Dong H, Yu Z, Ko K . Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice. Eur J Pharmacol. 2006; 552(1-3):170-5. DOI: 10.1016/j.ejphar.2006.09.011. View

17.

Simopoulos A . Evolutionary aspects of diet, the omega-6/omega-3 ratio and genetic variation: nutritional implications for chronic diseases. Biomed Pharmacother. 2006; 60(9):502-7. DOI: 10.1016/j.biopha.2006.07.080. View

18.

Puri P, Baillie R, Wiest M, Mirshahi F, Choudhury J, Cheung O . A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology. 2007; 46(4):1081-90. DOI: 10.1002/hep.21763. View

19.

Sanyal A, Mirshahi F, Rizzo W, Contos M, Sterling R, Luketic V . Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120(5):1183-92. DOI: 10.1053/gast.2001.23256. View

20.

Kleiner D, Brunt E, Van Natta M, Behling C, Contos M, Cummings O . Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41(6):1313-21. DOI: 10.1002/hep.20701. View